key: cord-0903191-06qr9m1d authors: Li, Hui; Gu, Xiaoying; Li, Huadong; Gong, Fengyun; Xu, Jiuyang; Wang, Yeming; Li, Haibo; Ruan, Shunan; Yang, Qingyu; Cao, Bin title: Risk factors of viral RNAaemia and its association with clinical prognosis among patients with severe COVID-19 date: 2021-01-06 journal: Chest DOI: 10.1016/j.chest.2020.11.071 sha: 8c1dc530c856147e4450c1f6612bbb56dadba52e doc_id: 903191 cord_uid: 06qr9m1d nan Coronavirus disease 2019 , caused by the severe acute respiratory 2 syndrome coronavirus 2 (SARS-CoV-2), poses a great threat to public health 3 worldwide. Around 5% of patients complicated with critical illness, with some of 4 them developing multi-organ dysfunction and even death [1, 2] . 5 One of the possible pathogenesis of multi-organ dysfunction in critical COVID-19 is 6 the direct attack of SARS-CoV-2 in multiple organs. Live virus particles have been 7 isolated from multiple sample types of specimens including stool [3] , urine [4] , as well as 8 respiratory specimens. However, how the virus further infects kidney and other organs 9 after infecting human through the respiratory tract remains unknown. One possible 10 explanation is the spread of virus through blood, as viral RNA has been detected in 11 blood of COVID-19 patients [5] , though live virus particle has not been successfully 12 isolated. In theory, patients with viremia are more prone to multiple organ 13 involvement and worse outcome. However, epidemiological evidence about 14 hypotheses of these associations and the risk factors of viral RNAaemia is lacking. 15 The aim of this study was to explore the dynamic features of viral RNA in blood, risk 16 factors of viral RNAaemia and association between RNAaemia and prognosis among 17 collected on day 1, 5, 10, 14, 21, 28 after enrollment or until discharge or death. 26 Detection of viral RNA was described previously [6] . E gene, RdRp gene, and N gene 27 of SARS-CoV-2 were all qualitatively tested and only E genes were quantitatively 28 detected. Limit of detection was 1000 copies per ml. Viral RNAaemia was defined as biologically associated with RNAaemia. The tests were two-sided and a p-value <0.05 43 was considered statistical significance. All results were analyzed with SAS, version 44 9.4 (SAS Institute, Inc., Cary, NC). 45 Of the 199 patients in the LOTUS study, 7 cases were excluded due to the lack of 47 was detected as early as 5 days after disease onset and remained positive as long as 30 53 days after disease onset in plasma of some patients ( Figure 1A) . Initial viral load in 54 the plasma of the 71 patients ranged from 3.37 to 6.63 log10 copies/ml. Positive rate 55 of viral RNAaemia was higher in deceased group before day 14 after illness onset 56 compared with the survived group ( Figure 1B ). Viral load in plasma of the deceased 57 COVID-19 patients was slightly higher than that of the survived patients before day 58 25 after illness onset ( Figure 1C) . Baseline viral load in throat swabs (4.8 ± 1.4 vs. 3.6 59 ± 0.9 Log10 copies per ml, p<0.001) and anal swabs (3.9 ± 1.1 vs. 3.3 ± 0.9 Log10 60 copies per ml, p<0.001) were higher in patients complicated with viral RNAaemia 61 than those without. Further correlation analysis shown that viral load in plasma was 62 positively associated with the baseline viral load in both throat swabs (r=0.34, 63 p<0.001) and anal swabs (r=0.29, p<0.001) (Fig 1D-F) . respectively. Long-term prior corticosteroid therapy before hospitalization was 70 associated with higher risk of viral RNAaemia (OR 5.00, 95% CI 1.21-20.59). 71 After multivariable adjustment for age, gender, and seven-category scale at baseline, 72 comorbidity, duration from illness onset to admission, antiviral treatment during 73 hospitalization, and corticosteroids treatment before and during hospitalization, viral 74 RNAaemia was found to be associated with increased risk of invasive mechanical 75 ventilation, ICU admission, and in-hospital death among severe COVID-19 patients. 76 RNAaemia was also found to be associated with acute kidney injury and ARDS, with 77 the risk of more than 10 folds among patients with viral RNAaemia compared with 78 those without RNAaemia ( Figure 2B ). In this study with 192 severe COVID-19 patients prospectively included and 81 longitudinal specimens collected, we found 37% of severe COVID-19 patients 82 hospitalized with pneumonia showed detectable SARS-CoV-2 viral RNA in plasma. storm [9] . 90 This study elucidated that higher viral loads in respiratory specimens and anal swabs 91 were positively associated with that in plasma, which indicated that for sites without 92 the ability to test viral RNA in blood, viral load in respiratory specimens and anal 93 swabs could indicate the possibility of viral RNAaemia. However, the indication may 94 be limited as the correlation was not strong. Furthermore, as no plaque assay was 95 performed to confirm the presence of live virus particles, it still needs further 96 investigation to determine whether the virus could be disseminated via blood. 97 To our knowledge, there are no reports about the risk factors of viral RNAaemia in 98 COVID-19 patients. As a universal immune-modulating agent, corticosteroid has been 99 considered for severe patients with respiratory virus infections. However, the 100 utilization of corticosteroids for patients with severe respiratory infection has always 101 been controversial for its adverse effect on delaying viral shedding and increasing the 102 risk of secondary infection [10] . Corticosteroids using was not found to be associated 103 with the increased occurrence of viral RNAaemia in COVID-19 patients. However, 104 prior corticosteroids therapy for underlying diseases was found to be an independent 105 risk factor for viral RNAaemia in COVID-19 patients. Large-Vessel Stroke as a Presenting Feature of 145 Covid-19 in the Young High risk of thrombosis in patients with severe 147 -2 infection: a multicenter prospective cohort study Epidemiologic Features and Clinical 150 Course of Patients Infected With SARS-CoV-2 in Singapore Isolation of Infectious SARS-CoV-2 from Urine 153 of a COVID-19 Patient Severe Acute Respiratory Syndrome 155 Coronavirus 2 RNA Detected in Blood Donations. Emerg Infect Dis A Trial of Lopinavir-Ritonavir in Adults Hospitalized 158 with Severe Covid-19 Comparative Effectiveness of Combined Favipiravir 160 and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients 161 With Influenza Virus Infection SARS-CoV-2 and viral sepsis: observations and 165 hypotheses The effect of corticosteroids on 167 mortality of patients with influenza pneumonia: a systematic review and 168 meta-analysis In conclusion, our study revealed that a high percentage of severe COVID-19 patients 107 complicated with viral RNAaemia, which is significantly associated with worse 108 outcomes. Patients with more severe baseline disease condition and prior 109 corticosteroids therapy for underlying diseases have higher risk of developing viral 110RNAaemia. Our data benefit a better understanding of pathogenesis of COVID-19 111 and provide a basis for the early identification and management of critically ill 112 patients. Coronavirus disease 2019 SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 ARDS Acute respiratory distress syndrome ALT Alanine aminotransferase ICU Intensive care unit